These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 11986689)

  • 1. [The recombinant vaccinia viruses expressing HPV type 16 wild or mutant E7 protein elicit immunity against tumor cells in mice].
    Zhi H; Han L; Ren J; Tian HW; Lao WF; Liang Y; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Sep; 15(3):222-5. PubMed ID: 11986689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experimental study of the immuno-protective activity of recombinant vaccinia virus expressing HPV58 E7].
    Luo LQ; Li J; Liu X; Zhang YH
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Feb; 25(1):43-6. PubMed ID: 12905606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Non-replicating recombinant vaccinia virus expressing HPV16 E6 and E7 proteins elicits anti-tumor immunity in mice].
    Luo WF; Han LQ; Ren J; Tian HW; Lu ZH; Zhao L; Gu SY; Ruan L
    Zhonghua Zhong Liu Za Zhi; 2003 Jul; 25(4):335-9. PubMed ID: 12921560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
    Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Modification of HPV type 16 E6 and E7 genes, and analysis of stability and immunogenicity of the modified proteins].
    Zhi H; Han L; Ren J; Tian H; Luo W; Liang Y; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Jun; 16(2):124-7. PubMed ID: 12196821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Construction of recombinant vaccinia virus co-expressing mutant E6 plus E7 proteins and detection of its immunogenicity and antitumor response].
    Zhi H; Han L; Ren J; Tian H; Luo W; Liang Y; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):341-4. PubMed ID: 12665900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice.
    Qin Y; Wang XH; Cui HL; Cheung YK; Hu MH; Zhu SG; Xie Y
    Gynecol Oncol; 2005 Feb; 96(2):475-83. PubMed ID: 15661238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin.
    Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC
    Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Jin HS; Park EK; Lee JM; NamKoong SE; Kim DG; Lee YJ; Jun HJ; Han BD; Bae SM; Ahn WS
    Gynecol Oncol; 2005 May; 97(2):559-67. PubMed ID: 15863160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
    Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
    Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunogenicity of mutant and wild HPV16 DNA vaccines].
    Zuo YG; Wang JB; Jin HZ; Yue-hua L
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):554-7. PubMed ID: 15562771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
    Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
    Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic, therapeutic and anti-metastatic effects of an HPV-16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model.
    Qian X; Lu Y; Liu Q; Chen K; Zhao Q; Song J
    Immunol Lett; 2006 Feb; 102(2):191-201. PubMed ID: 16242781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical immunogenicity and anti-tumour efficacy of a deleted recombinant human papillomavirus type 16 E7 protein.
    Hallez S; Brulet JM; Vandooren C; Maudoux F; Thomas S; Heinderickx M; Bollen A; Wattiez R; Jacquet A
    Anticancer Res; 2004; 24(4):2265-75. PubMed ID: 15330171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
    Daftarian P; Mansour M; Benoit AC; Pohajdak B; Hoskin DW; Brown RG; Kast WM
    Vaccine; 2006 Jun; 24(24):5235-44. PubMed ID: 16675074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein.
    Préville X; Ladant D; Timmerman B; Leclerc C
    Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cancer activity of plant-produced HPV16 E7 vaccine.
    Massa S; Franconi R; Brandi R; Muller A; Mett V; Yusibov V; Venuti A
    Vaccine; 2007 Apr; 25(16):3018-21. PubMed ID: 17280752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine.
    Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A
    Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.